Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;8(3):1901-1914.
doi: 10.1002/ehf2.13263. Epub 2021 Mar 3.

Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion

Andrew Constantine  1   2 , Robin Condliffe  3 , Paul Clift  4 , Robert Tulloh  5 , Konstantinos Dimopoulos  1   2 ; CHAMPION Steering Committee
Affiliations

Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion

Andrew Constantine et al. ESC Heart Fail. 2021 Jun.

Abstract

Aims: Pulmonary arterial hypertension (PAH) is common amongst patients with congenital heart disease (CHD). It is a severe and complex condition that adversely affects quality of life and prognosis. While quality of life questionnaires are routinely used in clinical pulmonary hypertension practice, little is known on how to interpret their results and manage PAH-CHD patients with evidence of impaired health-related quality of life, especially those with advanced disease and palliative care needs.

Methods and results: We performed a systematic review of studies concerning palliative care for people with PAH-CHD, also reviewing the health-related quality of life literature pertaining to these patients. Of 330 papers identified through initial screening, 17 were selected for inclusion. Underutilization of advance care planning and palliative care resources was common. Where palliative care input was sought, this was frequently late in the course of the disease. No studies provided evidence-based clinical criteria for triggering referral to palliative care, a framework for providing tailored care in this patient group, or how to manage the risk of sudden cardiac death and implantable cardioverter defibrillators in advanced PAH-CHD. We synthesize this information into eight important areas, including the impact of PAH-CHD on quality of life, barriers to and benefits of palliative care involvement, advance care planning discussions, and end-of-life care issues in this complex patient group, and provide expert consensus on best practice in this field.

Conclusions: This paper presents the results of a systematic review and expert statements on the preferred palliative care strategy for patients with PAH-CHD.

Keywords: Advance care planning; Congenital heart defects; End-of-life care; Palliative care; Pulmonary hypertension; Systematic review.

PubMed Disclaimer

Conflict of interest statement

All authors have been consultants to and have received grant support and personal fees from Janssen‐Cilag Limited during the conduct of the study. Dr Condliffe has received personal fees from Bayer and GlaxoSmithKline. Dr Clift has received personal fees from Bayer. Professor Tulloh has received personal fees from Pfizer, Abbott International, GlaxoSmithKline, and Bayer. Professor Dimopoulos has received grants and personal fees from Pfizer, GlaxoSmithKline, and Bayer/MSD.

Figures

Figure 1
Figure 1
The palliative care framework for patients with pulmonary arterial hypertension associated with congenital heart disease (PAH‐CHD) should take into account the unique characteristics and natural history of this condition. PAH‐CHD can be a rapidly progressive disease, affecting both quality of life (QoL) and prognosis. PAH therapies have now become integral to the management of most patients and are often escalated, aiming at a reduction in morbidity and mortality, and improvement in QoL. Despite this, patients can remain highly symptomatic; the early introduction of advance care planning (ACP) and palliative care can help to alleviate the impact of the disease and agree treatment goals with patients. The onset of congestive heart failure (HF) and/or progression of symptoms should further prompt palliative care involvement in parallel to escalation of PAH therapies (if appropriate) and transplant assessment. The palliative care framework and resources for PAH‐CHD patients should reflect the natural history of this disease, integrating components of acquired HF and lung disease care, but accounting for important differences: PAH‐CHD is an often‐aggressive disease with early onset of symptoms, especially in ES patients, and a high prevalence of multiorgan involvement. Moreover, PAH‐CHD patients are younger, with a different impact of the disease on their lives compared with older patients (school/studies/work/sport, etc.).
Figure 2
Figure 2
Barriers to effective palliative care involvement, involving different stakeholders of PAH‐CHD care, and recommendations for adapting care towards successful integration and provision of palliative care. +Misconceptions surrounding palliative care include the belief that palliative care is equivalent to end‐of‐life or hospice care, that is, it equates to ‘giving up’ or ‘losing hope’, is incompatible with active PAH therapy and is exclusively the remit of palliative care specialists. ACP, advanced care planning; EOL, end‐of‐life; PAH‐CHD, pulmonary arterial hypertension associated with congenital heart disease; PC, palliative care.
Figure 3
Figure 3
Multidimensional facets and goals of palliative care involvement. QoL, quality of life.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • The PAH patient's perspective.
    Jeffery DA, Gin-Sing W, Bedair R, Howard LS. Jeffery DA, et al. Int J Cardiol Congenit Heart Dis. 2025 May 26;21:100596. doi: 10.1016/j.ijcchd.2025.100596. eCollection 2025 Sep. Int J Cardiol Congenit Heart Dis. 2025. PMID: 40546754 Free PMC article. Review.
  • An interdisciplinary consensus approach to pulmonary hypertension in developmental lung disease.
    Varghese NP, Austin ED, Galambos C, Mullen MP, Yung D, Guillerman RP, Vargas SO, Avitabile CM, Chartan CA, Cortes-Santiago N, Ibach M, Jackson EO, Jarrell JA, Keller RL, Krishnan US, Patel KR, Pogoriler J, Whalen EC, Wikenheiser-Brokamp KA, Villafranco NM, Hopper RK, Usha Raj J, Abman SH; Pediatric Pulmonary Hypertension Network (PPHNet). Varghese NP, et al. Eur Respir J. 2024 Sep 26;64(3):2400639. doi: 10.1183/13993003.00639-2024. Print 2024 Sep. Eur Respir J. 2024. PMID: 39147412 Free PMC article. Review.

References

    1. Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis E, Vriend JWJ, van der Velde ET, Bresser P, Mulder BJM. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198–204. - PubMed
    1. Engelfriet PM, Duffels MGJ, Möller T, Boersma E, Tijssen JGP, Thaulow E, Gatzoulis MA, Mulder BJM. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93: 682–687. - PMC - PubMed
    1. Lowe BS, Therrien J, Ionescu‐Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58: 538–546. - PubMed
    1. Cha KS, Cho KI, Seo JS, Choi JH, Park YH, Yang DH, Hong GR, Kim DS. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol 2013; 112: 1834–1839. - PubMed
    1. Amedro P, Basquin A, Gressin V, Clerson P, Jais X, Thambo JB, Guerin P, Cohen S, Bonnet D. Health‐related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross‐sectional ACHILLE study. Cardiol Young 2016; 26: 1250–1259. - PubMed

Publication types

MeSH terms